tbuckley/cabot-search huggingface dataset:
Abstract 64: Correlation Of The Platelet Count With Immunoglobulin G, M, And A Levels In The Early Convalescent Stage Of Kawasaki Disease
Authors: Kyung-Yil Lee
Journal: Circulation (2015)

Background: The clinical course of Kawasaki disease (KD), which is self-limiting and immune-mediated, is controlled by the host’s immune system. The incidence of incomplete KD is increasing in Korea. We evaluate the changes in the platelet count and immunoglobulin (Ig) levels (IgG, IgM, IgA, and IgE) during hospitalization and the relationships among these parameters. Methods: We examined the platelet count and levels of the four above-mentioned Igs twice at presentation and at discharge (mean of 6.2 days apart) in 43 patients with complete KD who received intravenous Ig at 2 g/kg. The relationships across all parameters were evaluated. Results: The mean patient age was 29.9 ± 16.4 months, and there were 28 male and 15 female patients. The mean platelet count and IgG, IgM, IgA, and IgE levels at presentation and at discharge were 366 ± 92 and 548 ± 135 х10 3 /μL, 718 ± 317 and 2433 ± 426 mg/dL, 125 ± 45 and 234 ± 71 mg/dL, 63 ± 57 and 98 ± 79 mg/dL, and 69 ± 70 and 57 ± 64 IU/mL, respectively. The values of these parameters were correlated with the time of examination from fever onset, in comparing three groups with fever duration of the &lt;5 days, the 5-10 days, and the 11-16 days (Nonparametric Kruskal Wallis test and Dunn’s mehod for each post-hoc pair-wise test). A correlation was also noted in the degree of increase calculated at the two time points between the platelet count and IgG ( P = 0.002), IgM ( P = 0.01) or IgA level ( P = 0.002), respectively (Spearman correlation coefficient). Conclusions: The platelet count and Ig levels (IgG, IgM, and IgA) increased in the early convalescent stage of KD and were correlated with each other. This finding suggests that the host’s immune/repair system is involved in recovery from KD and may help to differentiate KD, especially incomplete KD, from other KD-like diseases if these phenomena do not occur in other diseases.
Calusterone in the therapy for advanced breast cancer
Authors: G. S. Gordan
Journal: JAMA (1972)

Dr. Theodore J. Hahn, Fellow in Endocrinology, the Jewish Hospital of St. Louis, and Assistant in Medicine, Washington University School of Medicine: A 58-year-old Negro woman was hospitalized on July 9, 1970, for treatment of metastatic carcinoma of the breast. The patient had experienced a normal menopause at age 50 years. Four years later, she was found to have a mass in her right breast which at operation proved to be an adenocarcinoma with axillary metastases. She underwent a right radical mastectomy and cobalt 60 radiation therapy to the axilla. The only evidence of metastatic disease at that time was an osteoblastic lesion, 3×5 cm in size, in the head of the right femur. This area was irradiated with cobalt 60 and to date has not progressed. The patient had been subsequently asymptomatic until May 1970, when she began to have gradually ing dyspnea on exertion, orthopnea, nonproductive cough, and
Meta-analyses Evaluating Diagnostic Tests
Authors: Les Irwig
Journal: Annals of Internal Medicine (1994)

Letters15 November 1994Meta-analyses Evaluating Diagnostic TestsLes Irwig, Anna N. A. Tosteson, and Constantine GatsonisLes IrwigSearch for more papers by this author, Anna N. A. TostesonSearch for more papers by this author, and Constantine GatsonisSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-121-10-199411150-00033 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We thank Dr. Wolf for his comments. Our aim in using the judgments of the three independent raters was to accept the majority view rather than to reach consensus among disparate views by discussion. Some meta-analysts prefer discussion because discrepancies are often caused by a rater missing a critical bit of information rather than by a difference in judgment.In principle, we agree that measures of inter-rater agreement would be of interest. In our article, based on only 11 studies, we did not calculate κ statistics because they would have had uninterpretably wide confidence intervals.We agree that ... Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 November 1994Volume 121, Issue 10Page: 817-818KeywordsConfidence intervals Issue Published: 15 November 1994 Copyright & PermissionsCopyright © 1994 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Highlights from this issue
Authors: A. Bush, I. Pavord
Journal: Thorax (2011)

The American Society of Regional Anesthesia and Pain Medicine (ASRA) periodically updates its practice advisories and associated cognitive aids. The 2020 version of the ASRA Local Anesthetic Systemic Toxicity checklist was created in response to user feedback, simulation studies and advances in medical knowledge. This report presents the 2020 version and discusses the rationale for its update.
Heparan sulfate proteoglycan expression in normal human liver
Authors: T ROSKAMS
Journal: Hepatology (1995)

Because increasing evidence implicates heparan sulfate proteoglycans (HSPGs) as essential cofactors in receptor-growth factor interactions, in cell-cell recognition systems, and in cell-matrix adhesion processes and yet little is known about their cellular distribution pattern and cellular sources in liver tissue, we used monoclonal antibodies specific for the core proteins of syndecan1, 2, 3, 4, glypican, and perlecan to investigate their immunohistochemical expression in normal adult human liver biopsy specimens. Syndecan1 was expressed in sinusoidal endothelial cells, whereas the endothelium of the portal tract vessels was negative. Hepatocytes showed a membranous staining pattern of the sinusoidal and intercellular domain. Bile duct epithelial cells showed basolateral membrane positivity. Immunoreactivity for syndecan2 was seen in mesenchymal cells, accentuated around bile ducts. Syndecan3 showed intense staining of hepatic arterial and portal venous endothelial cells, of mesenchymal cells, and of Ito cells. Immunohistochemistry for syndecan4 showed a granular staining pattern of hepatocytes at their bile canalicular pole. Glypican showed weak positivity in portal tract mesenchymal cells and clear positivity in nerve bundles. Perlecan was present in Disse's space, in endothelial cells, in basement membranes surrounding bile ducts and vessels, in vessel walls, and in mesenchymal cells. The highly differential expression of these HSPGs in the different cell compartments of the liver, as well as in basement membranes and in Disse's space, suggests that each of these proteoglycans has a specific function in the interplay of cells, matrix molecules, growth factors, and proteinases.(HEPATOLOGY 1995; 21:950–958.)
Building-associated risk of febrile acute respiratory diseases in Army trainees
Authors: J. F. Brundage
Journal: JAMA (1988)

Airborne transmission of infectious agents and associations of indoor air pollutants with respiratory illnesses are well documented. We hypothesized that energy conservation measures that tighten buildings also increase risks of respiratory infection among building occupants. At four Army training centers during a 47-month period, incidence rates of febrile acute respiratory disease were compared between basic trainees in modern (energy-efficient design and construction) and old barracks. Rates of febrile acute respiratory disease were significantly higher among trainees in modern barracks (adjusted relative risk estimate, 1.51; 95% confidence interval, 1.46 to 1.56), and relative risks were consistent at the four centers. These results support the hypothesis that tight buildings with closed ventilation systems significantly increase risks of respiratory-transmitted infection among congregated, immunologically susceptible occupants. (<i>JAMA</i>1988;259:2108-2112)
Management of Labor in the Primigravida with Breech Presentation
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
BEESON TO OXFORD
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reproductive toxicology. o-Cresol.
Authors: Jerry Heindel, Julia George, Patricia Fail, M Izard, Tom Grizzle
Journal: Environmental Health Perspectives (1997)

o-Cresol (OC) is widely used as a disinfec- tant, solvent, oil additive, component of creosote, and finds its way into air and water from various combustion processes.In previous 90-day prechronic toxicity study, murine estrous cycle was lengthened after exposure to OC.Because of the pre- liminary indications of toxicity and the relative paucity of public access information, OC was tested for its effects on reproduction and fertility in Swiss CD-1 mice using the RACB protocol.A 2-week dose-rangefinding study (Task 1) used feed concen- trations of 0.2 to 3% in feed.At 1% OC and above, adverse clinical signs appeared and weight loss was apparent.Mortality was significant at the 3% level.Thus, exposure concentrations for the Task 2 continuous cohabitation study were set at 0.05, 0.2, and 0.5% in feed.Based on mean feed consumption and body weight, the esti- mated dosages during Task 2 were approximately 60, 220, and 550 mg/kg/day.* * -I ---Estrous cycle length _
Pyelonephritis and Lower Urinary Tract Inflammation
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Traveler
Authors: Rachel Baumann Manzo
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors, followed by expansion cohorts in patients with FGFR genetic alterations.
Authors: Sarina Anne Piha-Paul, Cinta Hierro, Valentina Boni, Victor Moreno, Noah M. Hahn, Rhonda L. Bitting, Todd Michael Bauer, Rahul Raj Aggarwal, Steven Gourlay, Patrick Smith, Eleni Venetsanakos, Funda Meric-Bernstam, Ken Brameld, Dane Karr, Josep Tabernero
Journal: Journal of Clinical Oncology (2017)

TPS2616 Background: FGFR inhibition is a promising and clinically proven therapeutic approach in a number of solid tumors where genetic alterations of FGFR drive oncogenesis. PRN1371 is a highly selective oral, irreversible inhibitor of FGFR1-4 that exhibits high potency in cancer cell lines harboring FGFR alterations, including mutations and fusions. Methods: Part A of this phase 1 clinical trial explores ascending doses of PRN1371 in adult patients with advanced solid tumors in a "3 + 3" design, where cohorts of three patients are studied at each level until additional patients need to be added to better assess safety, establish the maximum tolerated dose and define the recommended phase 2 dose (RP2D). PRN1371 is dosed once or twice daily in continuous, 28-day cycles until disease progression. Part B studies include two or three expansion cohorts of different tumor types, 10 patients each with FGFR1-4 gene mutations, fusions, or amplification at the RP2D. The on-target effect of serum phosphorus and FGF23 increases are measured as potential pharmacodynamic biomarkers. Elevated serum phosphorus is managed with oral phosphate binding medications and a low phosphate diet, with dose interruptions and use of acetazolamide if certain thresholds are exceeded. Circulating tumor DNA from patients at baseline and during follow up is analyzed for FGFR genetic alterations. Pre and on-treatment tumor biopsies in Part B will be tested for a panel of pharmacodynamic biomarkers of FGFR inhibition. Clinical trial information: NCT02608125.
ACTIVE IMMUNIZATION AGAINST TYPHUS
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reply to Alberto Briganti, Giorgio Gandaglia, Markus Graefen, Steven Joniau, R. Jeffrey Karnes, and Francesco Montorsi’s Letter to the Editor re: Jean F.P. Lestingi, Giuliano B. Guglielmetti, Quoc-Dien Trinh, et al. Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial. Eur Urol 2021;79:595–604. Time for a Change? Clinically Meaningful Reasons Why We Will …
Authors: Jean F.P. Lestingi, Quoc-Dien Trinh, Rafael F. Coelho, Jose Pontes, Diogo A. Bastos, William C. Nahas
Journal: European Urology (2021)
Hematology
Authors: William H. Crosby
Journal: JAMA (1978)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Penance
Authors: Susan A. Glod
Journal: Annals of Internal Medicine (2016)

Ad Libitum6 December 2016PenanceSusan A. Glod, MDSusan A. Glod, MDFrom Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M16-1328 Audio Reading - “Penance” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Penance," by S.A. Glod. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail When I laughed at youThe crispness of my coat had begun to wiltAnd the magic of my pager was fading.I asked you so many questions.You asked me if I could understand how tired you were, andAfter 30 hoursAnd 40 patientsBut only 25 yearsI laughed, while your son lay dying.The only apology I can offerIs that when I watch a white coat begin to fadeAnd a pager become a burdenI tell your storyAnd hisAnd mine.And gradually, what once was penance has become a comfort.A hope that someone like meMay not fail someone like youQuite so muchThe next time.... Author, Article, and Disclosure InformationAffiliations: From Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania.Current Author Address: Susan A. Glod, MD, Penn State Milton S. Hershey Medical Center, Division of General Internal Medicine, Mail Code H106, 500 University Drive, PO Box 850, Hershey, PA 17033-0520; e-mail, [email protected]psu.edu. PreviousarticleNextarticle Advertisement Audio Reading - “Penance” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Penance," by S.A. Glod. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 6 December 2016Volume 165, Issue 11Page: 819 ePublished: 6 December 2016 Issue Published: 6 December 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Assessment of statistically significant changes in diastolic blood pressures
Authors: P. D. Varady
Journal: JAMA (1972)

To assess the result of any treatment of patients for the relief of hypertension, it is necessary to ascertain within what limits the blood pressures may vary in a series of hospital diastolic supine blood pressures. Only cases with at least nine hospital supine diastolic pressures were used. The population was then stratified into subjects with renovascular lesions and those with primary essential hypertension. The standard deviation for hospital diastolic supine blood pressures was found to be 10.23 mm Hg, regardless of the etiology of the hypertension. The large sample size in this report, with the corresponding stability of the estimate of blood pressure variability, enables these results to be used as a basis for definitions of therapeutic results.
Acetylsalicylic Acid Gastritis: Gastroduodenoscopic Observations
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal